Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CAS Medical's laser-based neonatal cerebral oximeter

This article was originally published in Clinica

Executive Summary

The Fore-Sight cerebral oximeter developed by CAS Medical Systems has received US FDA 510(k) clearance to be used in newborn babies weighing more than 2.5kg. The noninvasive device detects low cerebral oxygen saturation events using Branford, Connecticut-based CAS Medical's Laser-Sight technology. This works on the basis that blood contains both oxygenated and de-oxygenated haemoglobin; the two forms of haemoglobin absorb light in different, measurable ways. Laser light is projected through the scalp and skull and into the brain to detect levels of oxy and de-oxy haemoglobin. The reflected light is captured by a sensor and is analysed to determine cerebral tissue oxygen saturation. US launch of the Fore-Sight sensor is planned for the second half of 2008.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT046307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel